Glioma, especially glioblastoma and diffuse astrocytic glioma with the molecular characteristics of glioblastoma (a grade 4 astrocytoma), is the most frequent and aggressive type of brain tumour in adults. It presents extreme variability in appearance, shape, and composition, and patients with glioblastoma have a poor outlook. The standard treatment consists of surgery followed by radiotherapy and chemotherapy. The methylation status of the promoter of the DNA repair enzyme MGMT has been linked to a better prognosis in newly diagnosed glioblastoma and a better response to chemotherapy. Thus, determining these patients’ MGMT promoter methylation status can impact treatment decisions. The International Brain Tumor Segmentation (BraTS) Challenges, which started in 2012, evaluate the latest machine learning methods for analyzing brain tumour images in MRI scans.
Implementation of data augmentation pipelines for brain tumour structures. With a focus on “difficult” to-segment regions.
Implementation of noise reduction schemes for MRI scans (Diversity in acquisition protocols, device brand and modality)